Africa’s wild polio-free status to be determined in August
Brazzaville – The independent Africa Regional Certification Commission (ARCC), responsible for certifying the eradication of wild poliovirus in the World Health Organization (WHO) African Region, is set to make its final decision about the region’s wild poliovirus status in August 2020.
Following field verification visits over the past year and thorough critical analysis of the documentation of the polio surveillance, immunization and laboratory capacity presented by the governments of Cameroon, Central African Republic, Nigeria and South Sudan, the Commission has validated that the countries’ documentation grants them wild polio-free status.
In August 2019, the African Region became eligible to be certified free of wild poliovirus, after Nigeria, the last wild poliovirus endemic country, recorded no new cases three years – the requisite period – since it last reported cases of wild poliovirus. The commission had already accepted the documentation of the other 43 countries in the region.
“We are satisfied with the documentation that the four countries have presented. We are reviewing updated reports from the other 43 countries in the WHO African Region and we anticipate that by August 2020, we will deliver our final decision on the region’s certification status of wild poliovirus eradication,” said Professor Rose Leke, ARCC Chairperson.
“This achievement by Cameroon, Central African Republic, Nigeria and South Sudan is a major step towards the eradication of wild poliovirus in the African region,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “As the continent struggles with COVID-19, this milestone shows that when leaders, partners, health workers and communities come together we can triumph over the most difficult health challenges.”
If the region is certified in August, it would be the fifth of the six WHO regions to be declared free of wild polio. However, the scale of ongoing circulating vaccine-derived polio outbreaks is a battle the region is striving to win.
Efforts are underway to urgently address the circulating vaccine-derived poliovirus outbreaks, also within the context of polio eradication being a Public Health Emergency of International Concern. Even though they are not wild polioviruses, such rare strains – which can emerge in areas of low population immunity – also paralyse children.
WHO, UNICEF, Rotary International, the US Centers for Disease Control and Prevention, the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance continue to support governments in their efforts to stop the ongoing circulating vaccine-derived poliovirus outbreaks, including by implementing a new response strategy.
The aim is to ensure that no child anywhere in Africa will ever again be paralysed by any poliovirus – wild or vaccine-derived.
With the COVID-19 pandemic, mass immunizations across the region have been postponed until further notice, which hinders outbreak response activities. The polio eradication programme in the African Region, in addition to its support to the COVID-19 response, is working with countries to ensure the continuity of essential disease surveillance activities as well as planning the resumption of immunization and outbreak response in compliance with the guidance to stop COVID-19 transmission.
NCT04454788Not yet recruitingExtending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel OcclusionConditions: Ischemic Stroke
NCT04454801Not yet recruitingConditions: Anesthesia Education
NCT04454814CompletedConditions: Asymptomatic Molar Teeth With Periapical Lesions
NCT04454827CompletedConditions: Type 1 Diabetes Mellitus; Fear of Hypoglycemia
NCT04454840CompletedConditions: Amyotrophic Lateral Sclerosis
NCT04454853CompletedConditions: Paraneoplastic Neurological Syndrome
NCT04454866Not yet recruitingConditions: Penehyclidine; Postoperative Nausea and Vomiting; Bimaxillar Surgery
NCT04454879Not yet recruitingConditions: Renal Anemia
NCT04454892RecruitingConditions: Amyotrophic Lateral Sclerosis
NCT04454905Not yet recruitingConditions: Intrahepatic Cholangiocarcinoma
Featured Contract Research Organizations
AlphaGenesis Incorporated (AGI)
AGI has enjoyed tremendous success and growth throughout the years, and as we have grown, we have strengthened our dedication to providing only the be...
Kriger Research Group International (KRC)
Kriger Research Group International provides clinical research services for pharmaceutical and biotechnology product development from phase II through...
ClinOps Consulting is an independent service company, founded in 2008 in a joined effort of 2 senior profiles in Medical Devices and Pharmaceutical In...
ADDS (Advanced Drug Development Services)
Advanced Drug and Device Services SAS (ADDS) is a leading European Service Provider, contract Research and Safety Organization with offices in France,...